From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Event
Grade
Cilengitide + Gemcitabine n = 44
Gemcitabine n = 42
No.
Pts (%)
AE
All
923
100%
755
Grade 1/2
812
27%
617
17%
Grade 3/4
111
73%
138
83%
SAE
50
55%
64
71%